Age-Related Macular Degeneration

Type: Keyphrase

Name: Age-Related Macular Degeneration

First Reported Mar 20 2010 - Updated Mar 20 2010 - 1 Documents

Acucela, Otsuka Pharma get US FDA fast track status for ACU-4429

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd.,announced that they have received Fast Track designation from the US Food and Drug Administration ... [Published Mar 20 2010 by PharmaBiz]

Entities: Age-Related Macular Degeneration, Acucela Inc, Otsuka Pharmaceutical Co., Food and Drug Administration

First Reported Mar 20 2010 - Updated Mar 20 2010 - 1 Documents

Ireland: Carrots help boost vision

Antioxidants found in fruit and vegetables such as carrots can help slow down sight loss in older adults, say scientists.In a five-year study, scientists in Belfast and Waterford showed that the intake of high levels of both carotenoids - rich antioxidants ... [Published Mar 20 2010 by Fresh Plaza]

Entities: Age-Related Macular Degeneration, carotenoid, Ireland, Pigment, Zeaxanthin

First Reported Mar 18 2010 - Updated Mar 18 2010 - 4 Documents

University of California Irvine

International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogeneti

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB: ISCO.OB), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of ... [Published Mar 18 2010 by Yahoo! Canada]

Entities: Stem Cell, Retinal Pigment Epithelium, Age-Related Macular Degeneration, University of California Irvine, Parthenogenesis

First Reported Mar 18 2010 - Updated Mar 18 2010 - 1 Documents

Columbia University

Stephen Tsang, Columbia University - Keynote Speaker at Ocular Disease Conference

Stephen Tsang, Associate Director, Edward S. Harkness Eye Institute, Columbia University/New York Presbyterian Hospital will give a Keynote Presentation on Transplantation of Reprogrammed Embryonic Stem Cells Improves Visual Function in a Mouse Model ... [Published Mar 18 2010 by PR inside]

Entities: Columbia University, Retinitis Pigmentosa, GTCBio

First Reported Mar 17 2010 - Updated Mar 17 2010 - 1 Documents

Physician's Focus: Protecting Vision of Older Patients

Primary care physicians often may be the first to see precursory effects of diabetic retinopathy, age-related macular degeneration, and other sight-impairing conditions, making them point persons in protecting the vision of their older patients. To that ... [Published Mar 17 2010 by Modern Medicine]

Entities: Physician, Age-Related Macular Degeneration, Diabetic Retinopathy, Blepharitis

First Reported Mar 17 2010 - Updated Mar 17 2010 - 1 Documents

Acucela Gets FDA Fast Track

Biotech , Macular Degeneration , Drugs Luke Timmerman wrote:Acucela and its partner, Japan-based Otsuka Pharmaceutical, said today they have received “Fast Track” designation for an application to market a new drug for the “dry” form of age-related macular ... [Published Mar 17 2010 by Xconomy]

Entities: Food and Drug Administration, Otsuka Pharmaceutical Co., Luke Timmerman, Age-Related Macular Degeneration, Macular Degeneration

First Reported Mar 17 2010 - Updated Mar 17 2010 - 2 Documents

Food and Drug Administration

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration ... [Published Mar 17 2010 by News-Medical.Net]

Entities: Age-Related Macular Degeneration, Acucela Inc, Otsuka Pharmaceutical Co., Food and Drug Administration

First Reported Mar 16 2010 - Updated Mar 17 2010 - 2 Documents

Drug helps fight rare eye condition

An eye unit has revealed how Avastin helped save the sight of two people suffering with the rare condition, Sorsby's Fundus Dystrophy (SFD)Consultant ophthalmologist at Southampton General Hospital's eye unit, Professor Andrew Lotery, was the first to ... [Published Mar 17 2010 by Pharmacy Europe]

Entities: Age-Related Macular Degeneration, Retinal, fundus

First Reported Mar 17 2010 - Updated Mar 17 2010 - 1 Documents

Whitfield Clinic begins major trial in AMD

ennymaryanne.kenny@imt.ieThe Whitfield Clinic in Waterford is conducting a nationwide trial investigating the benefits of dietary nutrition supplements and their ability to preserve and enhance vision in patients with early age-related macular degeneration ... [Published Mar 17 2010 by Irish Medical Times]

Entities: Age-Related Macular Degeneration, Pigment, John Nolan, Waterford (Ireland), Dietary Supplements

First Reported Mar 16 2010 - Updated Mar 16 2010 - 1 Documents

Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

Hara R et al. The 12month results of PDT combined with IVB for Japanese patients with AMD without PCV appeared to be more effective than those of PDT alone with fewer treatments. ... [Published Mar 16 2010 by MDLinx]

Entities: Age-Related Macular Degeneration, photodynamic therapy

First Reported Mar 16 2010 - Updated Mar 16 2010 - 1 Documents

Sequenom Inc. Q4 2009 Earnings Call Transcript

Sequenom Inc. (SQNM)Q4 2009 Earnings CallMarch 15, 2010 4:30 pm ETExecutivesIan Clements – Senior Director, IR and Corporate CommunicationsHarry Hixson – Chairman and CEOPaul Maier – Interim CFOAnalystsZarak Khurshid – Wedbush SecuritiesEvan Lodes – Barclays ... [Published Mar 16 2010 by Seeking Alpha]

Entities: Paul Maier, Cantor Fitzgerald LP, Sequenom Inc

First Reported Mar 15 2010 - Updated Mar 15 2010 - 1 Documents

Bloomberg Radio Interviews William Caldwell, Advanced Cell Technology's Chairman and CEO

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced that company Chairman and Chief Executive Officer, William M. Caldwell IV, was interviewed recently on Bloomberg Radio's ... [Published Mar 15 2010 by TradingMarkets]

Entities: William Caldwell, Advanced Cell Technology Inc, Kathleen Hays, Age-Related Macular Degeneration

Quotes

Formatech's mission is to "Help make new drugs happen at the speed of science." About Tracon Pharmaceuticals, Inc

Formatech Donates Services to Formulate and Fill Tracon Pharmaceuticals' TRC102 Compound under... [Forbes.com - 1 hour ago]

...work with Formatech, one of the leaders in the field of drug product formulation and manufacture,' said Charles Theuer, Tracon’s President and CEO. "We are deeply appreciative that their Fillanthropy Program will allow us to continue our Phase 1 study of TRC102 in combination with Temodar for advanced cancer patients, and to initiate a Phase 2 study of TRC102 in combination with Alimta for patients with lung cancer."

Formatech Donates Services to Formulate and Fill Tracon Pharmaceuticalsâ TRC102 Compound under ... [EON - 1 hour ago]

More Content

sort by: Date \| Relevance
Formatech Donates Services to Formulate and Fil... [Forbes.com - 1 hour ago]
Formatech Donates Services to Formulate and Fil... [EON - 1 hour ago]
Acucela, Otsuka Pharma get US FDA fast track st... [PharmaBiz - Mar 20 2010]
Stem cells may be applied to model infant birth... [Health Jockey - Mar 20 2010]
French Biotech Neovacs SA Targets [BioSpace - Mar 20 2010]
Neovacs Testing European IPO Market; Seeks 20M... [BioWorld - Mar 20 2010]
Ireland: Carrots help boost vision [Fresh Plaza - Mar 20 2010]
Restoring Sight With Microchips [MedPage Today - Mar 19 2010]
Acucela and Otsuka obtain FDA fast track design... [Pharmacy Choice - Mar 19 2010]
Study shows that steroids target hemangioma ste... [News-Medical.Net - Mar 19 2010]
8. Acucela and Otsuka Pharmaceutical Receive FD... [AllBusiness Champions of Small Business - Mar 19 2010]
International Stem Cell Corporation Begins Its ... [Yahoo! Canada - Mar 18 2010]
International Stem Cell Corp. (ISCO.OB) to Cond... [International Business Times - Mar 18 2010]
ISCO commences second phase of testing RPE deri... [News-Medical.Net - Mar 18 2010]
Regeneron Announces Presentation at the Barclay... [FinanzNachrichten.de - Mar 18 2010]
International Stem Cell Corporation Begins Its ... [Zibb - Mar 18 2010]
Sequenom: Missing Analysts Expectations by Five... [Seeking Alpha - Mar 18 2010]
Stephen Tsang, Columbia University - Keynote Sp... [PR inside - Mar 18 2010]
Physician's Focus: Protecting Vision of Older P... [Modern Medicine - Mar 17 2010]
Acucela Gets FDA Fast Track [Xconomy - Mar 17 2010]
Advanced Cell Technology Announces Year-End Res... [FinanzNachrichten.de - Mar 17 2010]
Acucela, Otsuka Pharmaceutical granted FDA Fast... [News-Medical.Net - Mar 17 2010]
Acucela and Otsuka Pharmaceutical Receive FDA F... [FinanzNachrichten.de - Mar 17 2010]
They claim to foretell Alzheimer's to cancer, b... [Mail Online UK - Mar 17 2010]
Drug helps fight rare eye condition [Pharmacy Europe - Mar 17 2010]
DIAGNOSING WITH FUNDUS IMAGING SYSTEMS [Totally Optical - Mar 17 2010]
Whitfield Clinic begins major trial in AMD [Irish Medical Times - Mar 17 2010]
OVD issue highlights prevalence of eye problems... [News-Medical.Net - Mar 17 2010]
UK - The benifit of eggs [Meat Trade News Daily - Mar 17 2010]
Promedior completes $12M in financing [Philadelphia Inquirer - Mar 16 2010]

sort by: Date \| Relevance
QLT's Attractive Risk/Reward Profile [Long Investment Ideas from Seeking Alpha - Jan 28 2010] SeekingValue submits: QLT, Inc. (QLTI) will look to some like a failed pharmaceutical company with only one drug on the market, the sales of which have dropped almost ...
QLT's Attractive Risk/Reward Profile [Biotech Sector and Stocks Analysis from Seeking ... - Jan 28 2010] SeekingValue submits: QLT, Inc. (QLTI) will look to some like a failed pharmaceutical company with only one drug on the market, the sales of which have dropped almost ...
Alcon and Novartis Still Not Seeing Eye to Eye [Healthcare Sector and Stocks Analysis from Seek ... - Jan 24 2010] The Burrill Report submits: Alcon's (ACL) independent directors continued their battle to fend off Novartis' (NVS) avid interest in acquiring the eye-care company, ...
Novartis Eyes an Opportunity in Alcon [Biotech Sector and Stocks Analysis from Seeking ... - Jan 12 2010] The Burrill Report submits: Novartis (NVS) is pursuing plans to acquire the eye-care business Alcon (ACL) from Nestle (NSRGY.PK) in a controversial near-$50 billion ...
This Week's Biotech Deal-Making and Financing [Biotech Sector and Stocks Analysis from Seeking ... - Dec 20 2009] The Burrill Report submits: by MARIE DAGHLIANIn a busy week of deal-making and financing, Ambit Biosciences and Japan’s Astellas Pharma (ALPMF.PK) entered into a ...

Advanced Search Options

Age-Related Macular Degeneration